CACI International Inc (CACI) recently secured a 5-year contract worth $40 million to support development and fielding of chemical and biological defense equipment required to protect the U.S. armed forces.
Leveraging its leadership position in the Engineering-Technical and Logistics Domains of the Omnibus Program Engineering and Technical Support (:OPETS) contract, CACI International intends to expand its presence in the C4ISR (command, control, communications, computers, intelligence, surveillance, and reconnaissance). Moving forward, the contract is likely to foster significant growth for CACI International, as it entails the development of chemical and biological defense solutions to safeguard the armed forces against chemical and biological threats.
The company would work for the Department of Defense (DoD) Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), which is responsible for research, development, acquisition and lifecycle support of chemical and biological detection, protection and installation for critical missions abroad and in the U.S.
A leader in IT outsourcing for the U.S. federal government, CACI International has ample exposure to the DoD and Department of Homeland Security budgets. CACI International’s system-integration skills and intelligence expertise consume a significant portion of the funds earmarked for the Department of Homeland Security while creating systems that will facilitate sharing of critical information among all intelligence agencies.
Based in Arlington, Virginia, CACI International delivers IT applications and infrastructure to improve communications and secure the integrity of information systems and networks, enhance data collection and analysis, and increase efficiency and mission effectiveness.
The company faces tough competition from established players in the industry, which include formidable names such as Lionbridge Technologies Inc (LIOX) and EBIX Inc (EBIX).
CACI International currently has a Zacks Rank #4 (Sell). One of its competitors Innodota Inc (INOD) carries a Zacks Rank #2 (Buy).
More From Zacks.com